MedTrace Logo

Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA)

NCT01098201 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2015-09-21

No results posted yet for this study

Summary

This open-label pilot study will select subjects who are inadequate responders to methotrexate. These subjects will receive certolizumab subcutaneously on a monthly basis for six months. The study is attempting to determine the following:

1. Is lymphatic flow altered in the extremities of RA patients with an inflamed knee?
2. Is resolution of synovitis associated with a restoration of lymphatic flow and lymph node volume following therapy with certolizumab?
3. Can Doppler ultrasound be used to detect and follow alterations of lymph node size?

Conditions

Interventions

DRUG

Certolizumab

Subcutaneous administration on a monthly basis for six months

Sponsors & Collaborators

  • University of Rochester

    lead OTHER

Principal Investigators

  • Christopher Ritchlin, MD / MPH · University of Rochester

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01098201 on ClinicalTrials.gov